trials) which addresses the most important factors to be considered for a complex clinical trial
application in CTIS [20].
2.3 Validation, assessment and decision by Member States Concerned
The sponsor proposes an MSC to be RMS for a multinational clinical trial. During the validation
phase, the RMS will be selected by all MSCs on the basis of fair workshare and mutual
agreement. For mononational clinical trials, the MSC who receives the clinical trial application
is RMS by default. The RMS, in conjunction with MSCs, will validate if the clinical trial
application is complete and within scope of the CTR. If the clinical trial application is valid,
the assessment phase starts. The part I assessment is coordinated involving all MSCs and led
by the RMS who prepares a draft assessment report, sends the request for information (RFI)
with considerations, when applicable, (including also those from other MSCs, if applicable) to
the sponsor and issues a conclusion for the part I assessment after reviewing the answers to the
RFI.
The part II assessment is done by each MSC separately. Each MSC prepares an assessment
report part II, sends an RFI with considerations, if necessary, to the sponsor and issues a
conclusion of the part II assessment.
Within 5 days after part I and part II conclusions have been notified to the sponsor, each MSC
notifies the sponsor whether the clinical trial application is authorised, authorised subject to
conditions, or not authorised. The maximum timelines for each of these phases are provided in
Annex 2 of this quick guide.
The Part I conclusion of the RMS is also valid for the MSC, unless that MSC disagrees with
the conclusion of the RMS on the following grounds:
a. when it considers that participation in the clinical trial would lead to a subject receiving an
inferior treatment than in normal clinical practice in the MSC;
b. infringement of its national law
8
;
c. considerations regarding subject safety and data reliability and robustness were raised by
an MSC during the assessment coordinated review phase.
A sponsor can appeal in each Member State to a refusal on these grounds. Another ground to
appeal to a refusal is if the conclusion on part II is not acceptable. There could also be national
legislation applicable with respect to an appeal, e.g. allowing appeal also on an authorisation
with conditions.
Along the authorisation procedure, tacit approval or lapsed application principles apply:
− During the validation phase: a) if the RMS has not notified the sponsor within the applicable
timelines, the application will be considered complete and valid and b) when the sponsor
has not answered a request for information within the applicable timelines the application
shall be deemed to have lapsed in all MSCs.
− During the assessment phase: in case the sponsor does not answer a request for information
with respect to part I within the applicable timeline, the application shall be deemed to have
lapsed in all MSCs. In case the sponsor does not answer a request for information with
8
See CTR article 90, prohibiting or restricting the use of any specific type of human or animal cells, or the sale, supply or use of medicinal
products containing, consisting of or derived from those cells, or of medicinal products used as abortifacients or of medicinal products
containing narcotic substances within the meaning of the relevant international conventions in force such as the Single Convention on
Narcotic Drugs of 1961 of the United Nations.